L3VLUP
ProSign in

CYRX in the 13F filings

Cryoport Inc · CUSIP 229050307

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q1 2020
Quarter end
31 Dec 2020
the date the book describes
Filed
12 May 2021
latest of these filings; the earliest 12 Feb 2021
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
91
filed both Q3 2020 and Q4 2020; 0 listed it in both
Shares listed
1,145,891
combined, among listed positions
Reported value
$50m
combined, at the quarter end

Managers listing CYRX in Q4 2020

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2020, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
MFS Investment Management1,111,320$49munder 0.1%Addedn.a.12 May 2021 (the filing on sec.gov)
Quantbot Technologies LP21,928$962k0.10%Addedn.a.12 Feb 2021 (the filing on sec.gov)
PDT Partners LLC12,643$555kunder 0.1%Newnew16 Feb 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2020 to Q4 2020, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q2 2021 to 1 in Q2 2026

Tracked managers listing it, at least.

01232020202120222026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CYRX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20161$46kn.a.n.a.
Q2 20181$1.6mn.a.n.a.
Q3 20181$2.0mn.a.n.a.
Q2 20191$440kn.a.n.a.
Q3 20191$582kn.a.n.a.
Q1 20201$203kn.a.n.a.
Q3 20203$66mn.a.n.a.
Q4 20203$50mn.a.n.a.
Q1 20211$58mn.a.n.a.
Q2 20212$63mn.a.n.a.
Q3 20212$16mn.a.n.a.
Q4 20211$2.9mn.a.n.a.
Q1 20222$9.1mn.a.n.a.
Q3 20221$801kn.a.n.a.
Q4 20251$3.0m125
Q1 20261$6.2m109
Q2 20261$20m175

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CYRX and LLY →CYRX and JNJ →CYRX and VRTX →Choose a stock to compare with CYRX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CYRX, latest filings →Back to the 13F Explorer →